Image courtesy of University of LiverpoolThe research, conducted by the collaborative nanomedicine research program led by pharmacology professor Andrew Owen and materials chemistry professor Steve Rannard, from the University of Liverpool, examined the use of nanotechnology to improve the delivery of drugs to HIV patients.
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. This evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies using Solid Drug Nanoparticle (SDN) technology, which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
Presently, no clinically available oral nanotherapies exist for HIV populations and conventional pediatric HIV medicines are poorly available. The program examined one current paediatric formulation that utilizes high ethanol concentrations to solubilize lopinavir, a poorly soluble antiretroviral.
Through the use of a rapid small-scale nanomedicine screening approach developed at Liverpool, the researchers were able to generate a novel water dispersible nanotherapy, hence removing the need to use alcohol in the paediatric medicine.
The research, funded by the UK Engineering and Physical Sciences Research Council is in ongoing human trials, and the preclinical development has been published in Nature Communications. The title of the paper is ‘Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies’.
Professor Owen said “The fruits of our interdisciplinary research are beginning to be realized. Our approach has the potential to overcome challenges with current antiretroviral therapy, which include administration of high doses needed to achieve efficacious concentrations in the body, and the urgent need for better formulations for children living with HIV.”
Professor Rannard added, “The wide applicability of our strategy has implications for multiple therapy development programmes and we are actively engaged in the creation of nanomedicine options to impact a range of clinical needs.”